AbbVie Inc. — Form 8-K
Filed August 18, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
AbbVie executed Supplemental Indenture No. 13 on August 18, 2026, issuing nine series of senior notes totaling $9 billion: $500M floating rate notes due 2028, $1B at 4.500% due 2028, $1.25B at 4.650% due 2030, $1.5B at 4.875% due 2031, $1.25B at 5.050% due 2033, $1.5B at 5.300% due 2036, $1B at 5.450% due 2038, $1.5B at 6.000% due 2056, and $500M at 6.100% due 2066. All notes include a Special Mandatory Redemption provision (101% premium) if the Apogee Therapeutics acquisition agreement is terminated or not pursued. Trustee: U.S. Bank Trust Company, National Association.
Why this rating
$9B debt issuance is ~2.8% of AbbVie's $325B market cap—material financing for acquisition but routine capital raise relative to company size.
See more from August 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.